Quality of life research among melanoma patients that have been treated with immunotherapy, or targeted therapy and/or surgery

Quality of life research among melanoma patients that have been treated with immunotherapy, or targeted therapy and/or surgery - AILEEN study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55207

Enrollment

700

Registered

2020-12-01

Start date

2021-01-30

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kwaliteit van Leven Quality of Life

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - At least 18 years of age - Actively treated for melanoma by use of immunotherapy, targeted therapy, surgery or a combination. - Willing to fill in one questionnaire and perform one online cognition test.

Exclusion criteria

Exclusion criteria: - Insufficient understanding of the Dutch or English language

Design outcomes

Primary

Measure	Time frame
The primary study parameter is Health Related Quality of Life will be assessed with the he European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30).	—

Secondary

Measure	Time frame
The secondary outcome measurements will be gained from the use of the following questionnaires: the Melanoma Subscale and Melanoma Surgery Subscale of the Functional Assessment of Cancer Therapy * Melanoma (FACT-M), five questions about sociodemographic data, the Hospital Anxiety and Depression Scale (HADS), the Cancer Worry Scale (CWS), the immunotherapy-specific questionnaire, 4 questions about sexual health (EORTC sexuality module), social functioning (work ability) will be assessed with the work-ability questionnaire, patients will describe and value their experienced health (QUALY*s) with the 5-level EuroQOL-5D (EQ-5D-5L), and cognitive functioning will be assessed with the online Amsterdam Cognition Scan (ACS).	—

Measure

Time frame

The secondary outcome measurements will be gained from the use of the following questionnaires: the Melanoma Subscale and Melanoma Surgery Subscale of the Functional Assessment of Cancer Therapy * Melanoma (FACT-M), five questions about sociodemographic data, the Hospital Anxiety and Depression Scale (HADS), the Cancer Worry Scale (CWS), the immunotherapy-specific questionnaire, 4 questions about sexual health (EORTC sexuality module), social functioning (work ability) will be assessed with the work-ability questionnaire, patients will describe and value their experienced health (QUALY*s) with the 5-level EuroQOL-5D (EQ-5D-5L), and cognitive functioning will be assessed with the online Amsterdam Cognition Scan (ACS).

—

Countries

Netherlands

Outcome results